Huang et al., 2021 - Google Patents
CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphomaHuang et al., 2021
View PDF- Document ID
- 7314406645393083792
- Author
- Huang H
- Zhang J
- Hu Y
- Yang J
- Li W
- Zhang M
- Tian Y
- Wei G
- Zhang L
- Zhao K
- Tan B
- Cui J
- Qi Y
- Li Y
- Tian Q
- Wang Q
- Wu Y
- Li D
- Du B
- Liu M
- Publication year
External Links
Snippet
In recent years, chimeric antigen receptor (CAR) T cell therapy has shown great 31 promise in treating hematological malignancies. However, CAR T cell therapy 32 currently has several limitations. Here we successfully developed a two-in-one 33 approach to generate …
- 210000001744 T-Lymphocytes 0 title abstract description 84
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL | |
| US20210220404A1 (en) | Chimeric antigen receptors and uses thereof | |
| US20250034641A1 (en) | Cellular immunotherapy for repetitive administration | |
| AU2015330898B2 (en) | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | |
| JP2021534783A (en) | Method for producing chimeric antigen receptor-expressing cells | |
| JP2020195393A (en) | Engineered cells for adoptive cell therapy | |
| EP3686275A1 (en) | Gene editing t cell and use thereof | |
| KR20220147109A (en) | Methods for making chimeric antigen receptor-expressing cells | |
| JP2016525873A (en) | T cell balance gene expression, composition and method of use thereof | |
| EP3757133A1 (en) | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof | |
| US20210015866A1 (en) | Tissue resident memory cell profiles, and uses thereof | |
| JP2022545467A (en) | Combination therapy of T cell therapy with zeste homolog 2 enhancer (EZH2) inhibitors and related methods | |
| CN111212848A (en) | BRAF-specific TCRs and their uses | |
| EP4086341A1 (en) | Method for purifying ucart cell and use thereof | |
| WO2021136176A1 (en) | Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof | |
| Huang et al. | CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| Du et al. | CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell 2 non-Hodgkin lymphoma 3 | |
| Verma et al. | Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic stem cell tranplantation is predictive of subsequent relapse and survival | |
| US20250059591A1 (en) | Pct/us22/79410 | |
| RU2822196C2 (en) | Methods of producing cells expressing chimeric antigen receptor | |
| Zhu et al. | LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells | |
| Fessler | The Gut Microbiome Shapes the Tumor Microenvironment by Tuning Innate Immunity | |
| WO2023164439A2 (en) | Cd4+ t cell markers, compositions, and methods for cancer |